0-100 chain-logic scale · 15 dimensions · scored on public evidence
Концепции
NAD+ restoration for cellular resilience
Основная
MetroBiotech's central theory is that age-related decline or insufficiency in NAD+ can be therapeutically countered by proprietary oral NAD+ precursors such as MIB-626 and newer analogs such as MIB-725. By restoring and sustaining NAD+ availability, the intervention is expected to support mitochondrial function, gene regulation, and cellular resilience, which the company links to improved healthspan and treatment of age-related diseases.
Testable predictions are that treated humans should show increased circulating and tissue NAD+ or NAD-related metabolites, improved pharmacodynamic markers of NAD+ biology, and eventually better outcomes in age-related disease settings compared with placebo.
company website · Thu Jun 25 2026 15:03:04 GMT+0000 (Coordinated Universal Time) · Источник
Попперовская оценка
Premise plausibility7.0
The core premise is credible: NAD+ is tied to mitochondrial metabolism, NAD+-dependent enzymes, and stress responses, and the theory makes a direct claim that oral precursors should raise NAD+ biology in humans. The weak point is the jump from NAD+ insufficiency to broad age-related disease benefit. That final bridge is plausible, but thin in the provided evidence.
Подтверждающие доказательства: The theory specifies a mechanistic chain: oral precursor absorption, conversion into NAD+ or related metabolites, restoration in circulating and tissue compartments, then downstream effects on mitochondrial function and gene regulation.; The evidence context rates the human circulating NAD+ prediction as high confidence, which is the most near-term and testable part of the theory.
Контрдоказательства: No supporting publication in the provided context directly links MIB-626 or MIB-725 to improved age-related disease outcomes.; The broad claim that restored NAD+ improves healthspan has low confidence in the reasoning graph.
Explanatory power4.0
The theory explains why NAD+ metabolites and pharmacodynamic markers might move after treatment. It does not yet explain clinical aging outcomes better than simpler alternatives, such as a biomarker shift without durable tissue benefit, tissue-specific metabolism, or downstream pathways that do not meaningfully change disease course. Right now, it explains a biochemical intervention better than it explains aging.
Подтверждающие доказательства: The proposed mechanism connects a drug input to measurable NAD+ pathway outputs in humans.; The reasoning graph includes downstream markers of NAD+ biology, which gives the theory more structure than a generic supplement claim.
Контрдоказательства: The provided publications appear unrelated to NAD+ restoration and do not strengthen the explanatory case for MetroBiotech's theory.; The clinical-outcome prediction is marked low confidence, which means the theory has not yet earned the healthspan part of its explanation.
Falsifiability8.0
This is the strongest Popperian feature. The theory can be wrong in plain ways: MIB-626 or MIB-725 could fail to raise circulating NAD+ metabolites versus placebo, fail to raise tissue NAD+ measures, fail to shift pharmacodynamic markers, or fail in age-related disease endpoints despite biomarker movement. The theory would be sharper if it named compartments, doses, time windows, and minimum effect sizes.
Подтверждающие доказательства: The prediction that treated humans should show increased circulating NAD+ or NAD-related metabolites versus placebo is concrete and experimentally testable.; The theory also predicts tissue NAD+ changes, pharmacodynamic marker changes, and clinical benefit in age-related disease settings.
Контрдоказательства: The current formulation does not state a numeric threshold for a meaningful NAD+ increase.; The clinical prediction says outcomes should improve eventually, which leaves too much room to move the goalposts unless trials predefine endpoints and timing.
Дерево рассуждений
premise
Возрастное снижение уровня или недостаточность NAD+ — терапевтически значимый фактор, способствующий снижению клеточной устойчивости и развитию возрастных заболеваний.
medium confidence
assumption
assumes
Oral proprietary NAD+ precursors such as MIB-626 and newer analogs such as MIB-725 can be absorbed and converted into NAD+ or NAD-related metabolites in humans.
medium confidence
derivation
implies
Применение MIB-626 или MIB-725 должно восстановить и поддерживать доступность NAD+ в соответствующих циркулирующих и тканевых компартментах.
medium confidence
derivation
implies
Restored NAD+ availability should support mitochondrial function.
medium confidence
derivation
implies
Improved mitochondrial function and NAD+-dependent gene regulation should increase cellular resilience.
medium confidence
derivation
implies
Повышенная клеточная устойчивость должна приводить к увеличению продолжительности здоровой жизни и улучшению результатов лечения возрастных заболеваний.
low confidence
prediction
predicts
В условиях заболеваний, связанных со старением, у людей, получавших лечение, в конечном итоге должны наблюдаться лучшие клинические исходы, чем у людей, получавших плацебо.
low confidence
project_implication
requires
The project should prioritize human studies that measure NAD+ restoration, downstream pharmacodynamic effects, and clinical outcomes in age-related disease populations.
medium confidence
derivation
implies
Восстановленная доступность NAD+ должна поддерживать NAD+-зависимую регуляцию генов.
medium confidence
prediction
predicts
Humans treated with MIB-626 or MIB-725 should show increased circulating NAD+ or NAD-related metabolites compared with placebo.
high confidence
prediction
predicts
У людей, получавших MIB-626 или MIB-725, по сравнению с плацебо должно наблюдаться повышение уровня NAD+ в тканях или метаболитов, связанных с NAD+.
medium confidence
prediction
predicts
Treated humans should show improved pharmacodynamic markers of NAD+ biology compared with placebo.
medium confidence
Публичные одобрения
publicly endorses
David Sinclair publicly promotes MetroBiotech's NAD-booster program in his own social posts, describing MIB-626/NAD boosters as turning on the body's defenses, reporting human-study results as 'amazing,' and linking the approach to beneficial effects seen in mice. That goes beyond a neutral mention and aligns with the company's NAD+ restoration theory.
No relevant quote or publication ties this James Ellis to MetroBiotech or to NAD+ restoration for cellular resilience. The provided records appear unrelated or ambiguous, so there is no public evidence here of endorsement, mention, or contradiction.
silent
No provided quote or publication links Li-Huei Tsai to a public statement endorsing, mentioning, or contradicting MetroBiotech's NAD+ restoration theory. The supplied records do not show her discussing this theory directly.
silent
The provided evidence does not contain a public statement from Lindsay Wu endorsing, mentioning, or contradicting MetroBiotech's NAD+ restoration theory. The records show affiliations, financial interests, and related NAD(P)+ research context, but no attributable public comment by Wu on this specific company theory.
silent
The provided evidence contains no relevant public statement from Nick Lane about MetroBiotech, NAD+ restoration, MIB-626, or the company’s causal theory. The listed records appear unrelated or are false-positive name matches.
Oral precursor metabolic flux into tissue NAD+
MetroBiotech's metabolic flux research program tests the theory that orally administered NAD+ precursors such as NMN or NAM are absorbed, metabolized, and incorporated into NAD+ pools in humans, including in muscle tissue. This is a mechanistic bridge claim: the company's therapeutics can only plausibly affect aging-linked biology if oral dosing raises relevant NAD+ metabolites in blood and target tissues.
Testable predictions are that labeled or unlabeled oral precursors should increase NAD+ production or related metabolites in blood, urine, stool, and muscle biopsy samples, with measurable differences by age group, precursor type, dose, or duration.
company website · Thu Jun 25 2026 15:03:04 GMT+0000 (Coordinated Universal Time) · Источник
Попперовская оценка
Premise plausibility7.0
The premise is biologically credible: oral NMN and NAM can enter human metabolism, and the theory follows a coherent chain from absorption to metabolite handling to tissue NAD+ pools. The weaker step is muscle incorporation. Blood or urine changes can show exposure and metabolism, but they do not by themselves prove that target tissues raise NAD+ in a way that matters for aging-linked biology.
Подтверждающие доказательства: The theory names specific oral precursors, NMN and NAM, and links them to measurable NAD+ metabolites.; The reasoning chain separates absorption, metabolism, tissue incorporation, and therapeutic plausibility, which makes the mechanism internally coherent.; Muscle biopsy sampling is named directly, so the key tissue claim is at least addressable.
Контрдоказательства: The supplied evidence nodes list no supporting publication IDs for the NAD+ claims.; Blood, urine, and stool metabolite changes could reflect absorption and clearance without meaningful NAD+ elevation in muscle.; The claim that raising tissue NAD+ is necessary for aging-linked effects remains an assumption in the evidence context.
Explanatory power5.0
NAD+ precursor therapy for kidney injury and inflammation
MetroBiotech's COVID-19 acute kidney injury program proposes that MIB-626 may protect against worsening kidney function and attenuate inflammatory response in adults with COVID-19-associated stage 1 acute kidney injury. The implied causal mechanism is that NAD+ restoration improves cellular stress resistance and metabolic resilience during acute inflammatory and mitochondrial stress.
Testable predictions are that MIB-626-treated patients should have smaller longitudinal increases in serum creatinine, lower progression of acute kidney injury, reduced inflammatory markers, and increased blood NAD+ or NAD-related metabolites compared with placebo.
company website · Thu Jun 25 2026 15:03:04 GMT+0000 (Coordinated Universal Time) · Источник
Попперовская оценка
Premise plausibility6.0
The premise is biologically credible but still under-proven in this exact setting. NAD+ metabolism is tied to mitochondrial stress handling and cellular repair, so an NAD+ precursor could plausibly help kidney cells under acute inflammatory stress. The weak link is patient-specific: the evidence provided does not show that MIB-626 raises NAD+ metabolites in adults with COVID-19-associated stage 1 acute kidney injury, or that that change is enough to alter kidney outcomes.
Подтверждающие доказательства: The theory gives a coherent causal chain: MIB-626 increases NAD+ or related metabolites, NAD+ restoration improves stress resistance, and improved stress resistance reduces kidney-cell vulnerability.; The proposed readouts include both mechanism-linked biomarkers and clinical kidney measures, which fits the biology rather than floating above it.
Контрдоказательства: No supporting publication in the provided context directly tests MIB-626 in COVID-19-associated acute kidney injury.; The supplied publication list appears mostly unrelated to NAD+, kidney injury, or COVID-19 acute kidney injury.
Explanatory power4.0
NAD+ support for mitochondrial bioenergetics
MetroBiotech's Friedreich's Ataxia and performance-oriented programs imply a causal theory that raising NAD+ with MIB-626 should improve mitochondrial-linked bioenergetics in tissues such as cardiac and skeletal muscle. The mechanism is that NAD+ is a core metabolic cofactor, so increasing NAD+ availability should improve cellular energy metabolism in disorders or contexts where mitochondrial function is impaired or limiting.
Testable predictions are that MIB-626-treated participants should show measurable changes in cardiac or skeletal muscle bioenergetics, exercise-related metabolism, endurance, or muscle performance, with corresponding increases in NAD+ pathway metabolites.
company website · Thu Jun 25 2026 15:03:04 GMT+0000 (Coordinated Universal Time) · Источник
Попперовская оценка
Premise plausibility7.0
The premise is biologically credible: NAD+ is a core metabolic cofactor, and raising NAD+ metabolites could plausibly change energy metabolism in tissues with mitochondrial stress. The weak point is constraint. The theory assumes NAD+ availability is limiting in Friedreich's Ataxia or performance contexts, but the supplied evidence does not show that MIB-626 reaches cardiac or skeletal muscle at a level that changes bioenergetics.
Подтверждающие доказательства: The theory states that MIB-626 is intended to raise NAD+ availability.; The reasoning graph rates the premise that NAD+ is involved in cellular energy metabolism as high confidence.; The causal chain is internally coherent: raise NAD+, alter NAD+ pathway metabolites, then test cardiac or skeletal muscle bioenergetics.
Контрдоказательства: The key assumption that NAD+ availability constrains bioenergetics in these contexts is only medium confidence.; No supplied publication directly tests MIB-626, Friedreich's Ataxia, cardiac bioenergetics, skeletal muscle bioenergetics, endurance, or muscle performance.
Explanatory power3.0
The theory explains a proposed program logic better than it explains observed evidence. We have a plausible mechanism, but almost no relevant outcome data in the provided context. Without measured NAD+ metabolite increases plus linked changes in muscle or cardiac function, the theory cannot yet beat simpler explanations such as general metabolic noise, training effects, placebo effects in performance measures, or disease variability.
NAD+ biology for muscle performance and endurance
MetroBiotech's exercise and physical performance program implies that NAD+ precursor treatment could improve muscle strength, endurance, or adaptation to training by supporting mitochondrial function and energy metabolism. If true, MIB-626 or related NAD+ precursor dosing should produce measurable improvements in physical performance endpoints, potentially alone or combined with high-intensity multidimensional exercise training.
The biological premise is credible at the broad level: NAD+ is tied to mitochondrial metabolism, and skeletal muscle performance depends heavily on energy handling. The weak point is tissue relevance. The provided evidence does not show that MIB-626, or any related NAD+ precursor, raises NAD+ in skeletal muscle at a level that changes strength, endurance, or training response.
Подтверждающие доказательства: The theory states a coherent chain: NAD+ precursor dosing could raise NAD+ availability, support mitochondrial function, and improve muscle performance or training adaptation.; The reasoning nodes identify muscle strength, endurance, exercise capacity, and adaptation to training as the relevant endpoint family.
Контрдоказательства: The evidence context says the provided publications do not directly evaluate NAD+ precursors, MIB-626, mitochondrial muscle biology, endurance, strength, or training adaptation.; The key tissue assumption, higher biologically relevant NAD+ availability in skeletal muscle, is asserted with medium confidence rather than shown here.
Explanatory power2.0
The theory explains very little in this evidence packet because there is no relevant performance evidence to explain. The cited publications concern mirtazapine for methamphetamine use disorder, tamarind extract docking for depression-related targets, pediatric vein catheterization, and juvenile idiopathic arthritis recommendations. None bears on NAD+ precursor effects in exercise physiology.
NAD+ restoration to protect kidney function during acute injury
The COVID-19 acute kidney injury program proposes that MIB-626 may prevent worsening kidney function and attenuate inflammatory response in adults with COVID-19 and stage 1 acute kidney injury. Mechanistically, the theory links NAD+ restoration to improved cellular stress handling during acute inflammatory and renal injury. Testable predictions include better longitudinal serum creatinine trajectories and reduced inflammatory response versus placebo.
The premise is biologically credible at the sketch level: acute kidney injury stresses renal cells, COVID-19 can drive inflammatory injury, and NAD+ biology is plausibly tied to cellular stress handling. The weak point is directness. The supplied evidence does not show that MIB-626 restores NAD+ in the relevant kidney or inflammatory compartments, or that this restoration changes creatinine trajectories in COVID-19 stage 1 acute kidney injury. So the premise is plausible, but under-supported here.
Подтверждающие доказательства: The theory names a defined intervention, MIB-626, in adults with COVID-19 and stage 1 acute kidney injury.; The mechanism links NAD+ restoration to cellular stress handling during acute inflammatory and renal injury.; The proposed clinical effects are concrete: less worsening kidney function and lower inflammatory response.
Контрдоказательства: The evidence context states that the supplied publications do not directly report MIB-626, NAD+ restoration, COVID-19 acute kidney injury, serum creatinine trajectories, or renal inflammatory outcomes.; The key bridge from MIB-626 exposure to renal NAD+ restoration is listed as an assumption with medium confidence.
Explanatory power3.0
The theory has little explanatory power against the supplied evidence because there is no relevant observed treatment result to explain. It could explain better creatinine trajectories and reduced inflammation if those outcomes appear in a placebo-controlled trial, but that is still conditional. Right now, alternative explanations such as baseline AKI severity, COVID-19 course, fluid status, nephrotoxic drug exposure, and standard supportive care remain wide open.
Oral NAD+ precursor metabolic flux
A more specific mechanistic theory is that orally administered NAD+ precursors are absorbed and metabolized into NAD+ in humans, including in muscle and other tissues. If this theory is correct, labeled or unlabeled NMN/NAM dosing should produce measurable increases in NAD+ and related metabolites in blood, urine, stool, and muscle biopsy samples, with older adults showing pharmacodynamic evidence of NAD+ repletion after short-term treatment.
The premise is biologically credible: oral NAD+ precursors can plausibly enter human metabolism, and the theory names NAD+ and related metabolites as the readout. The weaker part is tissue reach. Blood and urine changes are easier to believe than a clear rise in muscle NAD+ after short-term dosing, because circulation and excretion can move without proving durable intracellular repletion.
Подтверждающие доказательства: The reasoning chain states that orally administered NAD+ precursors are absorbed in humans.; The theory predicts measurable NAD+ and related metabolite changes in blood, urine, stool, and muscle biopsy samples.; The project implication correctly identifies multi-compartment metabolomics as the required test.
Контрдоказательства: The provided reasoning nodes have no supporting publication IDs.; The theory assumes metabolite increases after dosing validly indicate flux into NAD+ pools, but that assumption is only medium confidence.; Muscle repletion is a stronger claim than absorption, and the supplied context gives no direct biopsy data.
Explanatory power5.0
The theory explains a specific pattern: NAD+ precursor dosing should move NAD+ pathway metabolites across several human sample types. But with the evidence supplied here, it does not yet beat simpler alternatives. A rise in blood or urine metabolites could reflect absorption, first-pass metabolism, renal clearance, or transient spillover rather than meaningful NAD+ repletion inside muscle.
Next-generation NAD+ analogs for age-related disease
MetroBiotech's MIB-725 program extends the same NAD+ biology theory to newer proprietary NAD+ analog therapeutics. The causal claim is that optimized NAD+ restoration compounds may sustain or improve NAD-linked biology relevant to aging, metabolism, and age-related diseases, potentially improving on earlier precursor approaches.
Testable predictions are that MIB-725 should be tolerable in early human dosing, increase or modulate NAD-related pharmacodynamic markers, and show disease-relevant biological effects in later trials if NAD+ restoration is causally linked to the targeted age-related pathology.
company website · Tue Jun 02 2026 23:15:21 GMT+0000 (Coordinated Universal Time) · Источник
Попперовская оценка
Premise plausibility6.0
The premise is credible at the biology level: NAD-linked pathways do connect to aging, metabolism, mitochondrial function, and stress responses. The weaker part is the jump from restoring NAD-related markers to treating age-related disease. The evidence supplied gives no MIB-725 human data, no tissue exposure data, and no disease endpoint, so the premise rests on a plausible mechanism rather than demonstrated therapeutic causality.
Подтверждающие доказательства: The theory specifies NAD-linked biology as relevant to aging, metabolism, and age-related diseases.; The stated predictions include tolerability, NAD-related pharmacodynamic marker changes, and later disease-relevant biological effects.
Контрдоказательства: No supporting publications are attached to the NAD+ reasoning nodes.; The provided publication list appears unrelated to MIB-725 or NAD+ analog therapeutics.; The theory assumes pharmacologically meaningful NAD+ restoration in relevant human tissues, but no tissue data are provided.
Explanatory power3.0
The theory explains what MetroBiotech hopes MIB-725 will do, but it does not yet explain observed disease benefit because no such observation is included. Marker movement, if shown, would still have competing explanations: exposure, metabolic compensation, or nonspecific pathway modulation. The causal claim needs a tighter bridge between NAD biology and a named pathology.
MIB-626 as an NAD+ precursor therapeutic
MetroBiotech's MIB-626 program is based on the claim that a proprietary NAD+ precursor can pharmacologically increase NAD+ availability in humans, rather than relying on dietary supplementation or indirect lifestyle effects. The implied causal mechanism is that increasing NAD+ substrate availability should replenish NAD-dependent cellular pathways involved in energy metabolism, mitochondrial function, gene regulation, and stress response.
Testable predictions are that MIB-626 dosing should produce measurable increases in blood NAD+ and related metabolites within days to weeks, should do so without unacceptable safety signals, and should support later trials testing whether NAD+ elevation translates into clinical outcomes in age-related or mitochondrial-linked conditions.
company website · Tue Jun 02 2026 23:15:21 GMT+0000 (Coordinated Universal Time) · Источник
Попперовская оценка
Premise plausibility6.0
The premise is biologically credible at the first step: an NAD+ precursor can, in principle, raise measurable NAD+ or related metabolites in humans if it is absorbed and converted. The harder claim is tissue relevance. Blood NAD+ movement does not prove that mitochondria, nuclei, or stressed tissues receive enough NAD+ to change function. The theory is plausible, but it leans on two bridges that are still weak here: compartment access and clinical meaning.
Подтверждающие доказательства: The theory names a direct pharmacodynamic prediction: MIB-626 dosing should raise blood NAD+ and related metabolites within days to weeks.; The proposed pathway is internally coherent: precursor availability could feed NAD-dependent processes involved in energy metabolism, mitochondrial function, gene regulation, and stress response.; The program correctly treats pharmacodynamic NAD+ elevation and tolerability as prerequisites before claiming benefit.
Контрдоказательства: The evidence context gives no MIB-626 human trial result showing the predicted NAD+ increase.; Blood NAD+ and related metabolites are only proxy compartments; they may not track NAD+ availability in the tissues that matter for disease.; The link from higher NAD+ to clinical benefit in age-related or mitochondrial-linked conditions is marked low confidence.
silent
The provided evidence only shows Rajendra Apte's academic and ophthalmology-related roles and talks, with no public statement from him about MetroBiotech, NAD+ restoration, MIB-626, or the company's causal theory.
The theory explains why oral precursor dosing could produce metabolite shifts across blood, urine, stool, and muscle. It does less well at explaining aging-linked biology, because the supplied evidence stops at flux and pool entry. A simpler explanation could fit many observations: the compound is absorbed, processed, and excreted, while target-tissue NAD+ biology remains modest or inconsistent.
Подтверждающие доказательства: The theory predicts measurable metabolite changes in multiple sample types after oral dosing.; It can account for differences by age group, precursor type, dose, and dosing duration.; The therapeutic bridge is explicit: MetroBiotech's approach needs target-tissue metabolite changes to be plausible.
Контрдоказательства: No direct evidence is provided that metabolite changes explain functional aging-linked outcomes.; Changes in blood or urine could arise from first-pass metabolism or excretion rather than durable tissue NAD+ restoration.; The listed publications in the evidence context do not appear to support this NAD+ theory.
Falsifiability9.0
This is the strongest Popperian feature. The theory makes concrete, measurable predictions: oral precursors should change NAD+ production or related metabolites in blood, urine, stool, and muscle biopsy samples, with differences by age, compound, dose, or duration. A well-controlled tracer study that finds no precursor-derived signal in muscle NAD+ pools would hit the core claim directly.
Подтверждающие доказательства: The theory specifies observable sample types: blood, urine, stool, and muscle biopsy.; It allows labeled precursor testing, which can distinguish precursor-derived metabolites from background NAD+ turnover.; It predicts structured variation by age group, precursor type, dose, and dosing duration.
Контрдоказательства: The theory does not specify effect-size thresholds, timing windows, or minimum tissue NAD+ changes needed for success.; Without predefined thresholds, weak or transient metabolite shifts could be over-read as support.; The link from tissue flux to aging-linked biology needs separate falsifiable endpoints.
Дерево рассуждений
premise
Orally administered NAD+ precursors such as NMN or NAM are absorbed and enter human metabolism.
medium confidence
derivation
implies
Absorbed oral NAD+ precursors are metabolized into NAD+ or related NAD+ metabolites in humans.
medium confidence
derivation
implies
Метаболизированные пероральные предшественники NAD+ включаются в пулы NAD+ в тканях человека, включая мышечную ткань.
medium confidence
project_implication
requires
MetroBiotech therapeutics based on oral NAD+ precursors are mechanistically plausible only if oral dosing raises relevant NAD+ metabolites in blood and target tissues.
high confidence
assumption
assumes
Повышение уровня метаболитов NAD+ в крови и целевых тканях необходимо, чтобы пероральные терапевтические средства — предшественники NAD+ — воздействовали на биологические процессы, связанные со старением.
medium confidence
prediction
predicts
Labeled or unlabeled oral NAD+ precursors should increase NAD+ production or related metabolites in blood samples.
high confidence
prediction
predicts
Меченые или немеченые пероральные предшественники NAD+ должны увеличивать выработку NAD+ или родственных метаболитов в образцах мочи.
high confidence
prediction
predicts
Labeled or unlabeled oral NAD+ precursors should increase NAD+ production or related metabolites in stool samples.
medium confidence
prediction
predicts
Меченые или немеченые пероральные предшественники NAD+ должны повышать выработку NAD+ или родственных метаболитов в образцах мышечной биопсии.
high confidence
prediction
predicts
Метаболические реакции на предшественник NAD+ должны различаться в зависимости от возрастной группы.
medium confidence
prediction
predicts
Метаболические реакции на предшественники NAD+ должны различаться в зависимости от типа предшественника.
medium confidence
prediction
predicts
Метаболические реакции на предшественник NAD+ должны различаться в зависимости от дозы.
medium confidence
prediction
predicts
Метаболические реакции на прекурсор NAD+ должны различаться в зависимости от длительности дозирования.
Sinclair publicly promotes MetroBiotech's NAD-booster program. In the Facebook post, he says MetroBiotech is developing NAD boosters for age-related disease and that ongoing human-study results for MIB-626 have been "amazing." In the 2017 video/article excerpt, he links NMN, NAD+, and MetroBiotech's human-trial plans. He does not spell out the full tissue-flux mechanism here, but he is clearly endorsing the core precursor-to-NAD therapeutic premise rather than distancing himself from it.
The evidence provided does not show this James Ellis discussing MetroBiotech, NAD+ precursors, NMN, NAM, or oral metabolic flux into tissue NAD+. The records look unrelated, including a swim video and author pages for a different James Ellis. On this dossier, there is no public endorsement, mention, or contradiction of the theory.
The evidence provided does not show Li-Huei Tsai discussing MetroBiotech's theory that oral NAD+ precursors raise NAD+ metabolites in blood or tissue. The listed records are either about Andrew Huberman and NMN market access, or a Boston Globe article whose excerpt here does not contain any statement from Tsai on this mechanism. With no direct quote, publication, or attributed statement from her, the defensible call is silence.
Lindsay Wu appears in the 2017 MetroBiotech-related video/article describing NMN as the molecule he and David Sinclair were developing into a drug, and he says, "we believe we can with this molecule" in the context of NAD-linked repair and aging claims. That is a public mention of the broader NMN/NAD program, but this record does not clearly state the specific metabolic-flux claim that oral precursors are absorbed and incorporated into human blood and muscle NAD+ pools.
The provided evidence does not show Nick Lane discussing MetroBiotech, NAD+ precursors, NMN, NAM, or oral metabolic flux into tissue NAD+. Every listed record is irrelevant or appears to match different people or unrelated uses of "Nick Lane" and "Metro," so there is no public endorsement, mention, or contradiction here.
silent
No provided evidence shows Rajendra Apte discussing MetroBiotech's NAD precursor theory, oral NMN or NAM uptake, or tissue NAD+ incorporation. The dossier only documents his ophthalmology and aging-related work, plus founder activity in macular degeneration, which does not amount to a public statement on this theory.
The theory could explain better creatinine trajectories, lower AKI progression, and reduced inflammatory markers if those effects appear together with higher NAD+ metabolites. Right now, it mostly explains a hoped-for pattern, not observed evidence. COVID-19 kidney injury has many competing explanations: hemodynamics, viral illness severity, inflammation, thrombosis, nephrotoxic drugs, and baseline kidney reserve. Without trial results tying MIB-626 to both NAD+ restoration and kidney protection, the explanatory claim stays modest.
Подтверждающие доказательства: The theory links metabolic stress resistance to both kidney-function endpoints and inflammatory biomarkers.; The prediction set would be more convincing if the biomarker change and clinical benefit moved in the same direction.
Контрдоказательства: No observed MIB-626 outcome data are provided for serum creatinine, AKI progression, inflammatory markers, or NAD+ metabolites.; Alternative explanations for kidney recovery in COVID-19-associated stage 1 AKI are common and could explain improved creatinine without requiring NAD+ restoration.
Falsifiability8.0
This theory is testable in a clean way. A placebo-controlled study can measure serum creatinine over time, AKI progression, inflammatory markers, and blood NAD+ or related metabolites. If MIB-626 fails to raise NAD+ metabolites, the mechanism takes a direct hit. If NAD+ rises but kidney and inflammatory outcomes do not move, the therapeutic claim weakens sharply. That is real Popperian exposure.
Подтверждающие доказательства: The theory names concrete placebo-comparator predictions: smaller creatinine increases, lower AKI progression, lower inflammatory markers, and higher NAD+ or NAD-related metabolites.; The predictions include both mechanistic and clinical endpoints, so failure can localize to target engagement or downstream efficacy.
Контрдоказательства: The provided theory text does not specify exact effect sizes, sampling windows, inflammatory markers, or AKI progression thresholds.; Stage 1 AKI can resolve spontaneously, so trial design needs enough power and careful baseline adjustment.
Дерево рассуждений
premise
MIB-626 предлагается в качестве терапии — предшественника NAD+ — для взрослых с острым повреждением почек 1-й стадии, связанным с COVID-19.
medium confidence
assumption
assumes
Лечение MIB-626 восстанавливает или повышает уровни системного NAD+ или метаболитов, связанных с NAD+, в целевой популяции пациентов.
medium confidence
derivation
implies
Восстановление уровня NAD+ повышает устойчивость клеток к стрессу во время острого воспалительного и митохондриального стресса.
medium confidence
derivation
implies
Повышенная устойчивость клеток к стрессу и метаболическая устойчивость снижают уязвимость клеток почек при остром повреждении, ассоциированном с COVID-19.
medium confidence
project_implication
implies
MIB-626 может защищать от ухудшения функции почек у взрослых с острой почечной недостаточностью 1-й стадии, ассоциированной с COVID-19.
medium confidence
prediction
predicts
Compared with placebo, MIB-626-treated patients should show smaller longitudinal increases in serum creatinine.
high confidence
prediction
predicts
По сравнению с плацебо у пациентов, получавших MIB-626, должно наблюдаться менее выраженное прогрессирование острого повреждения почек.
high confidence
project_implication
implies
MIB-626 может ослаблять воспалительный ответ у взрослых с ассоциированным с COVID-19 острым повреждением почек 1-й стадии.
medium confidence
prediction
predicts
По сравнению с плацебо у пациентов, получавших MIB-626, должно наблюдаться снижение маркеров воспаления.
high confidence
prediction
predicts
По сравнению с плацебо у пациентов, получавших MIB-626, должно наблюдаться повышение уровня NAD+ в крови или метаболитов, связанных с NAD.
Sinclair publicly backs MetroBiotech's NAD-booster platform in general. In the Facebook post, he says MetroBiotech is developing NAD boosters that "turn on the body's defenses" and reports strong human-study results. In the 2017 video/article excerpt, he also ties NAD+ boosting with NMN to improved DNA repair and cellular resilience. That is directionally consistent with the theory's NAD-restoration mechanism, but the provided evidence does not show him publicly endorsing the specific COVID acute kidney injury and inflammation claim.
The evidence does not show this James Ellis discussing MetroBiotech, MIB-626, NAD+ restoration, kidney injury, or COVID-19 inflammation. The records look like unrelated web pages and a swim video, so they do not support an endorsement, mention, or contradiction.
The provided evidence does not show Li-Huei Tsai publicly endorsing, mentioning, or contradicting MetroBiotech's theory that NAD+ precursor therapy could protect against COVID-19-related acute kidney injury and inflammation. The records reference NMN/NAD+ discussion by Andrew Huberman and a Boston Globe article about memory research, but none tie Tsai to this kidney-injury mechanism or program.
Lindsay Wu is publicly tied to MetroBiotech's NAD+ booster work in the 2017 video record, which says he and David Sinclair were developing NMN-based drug candidates at MetroBiotech and quotes Wu saying they believe the molecule can address accelerated aging and DNA-damage-related disease. That is a public mention of the broader NAD+ restoration idea. It does not specifically endorse the narrower claim that MIB-626 protects COVID-19 patients with stage 1 acute kidney injury or reduces kidney inflammation markers.
The evidence provided does not show Nick Lane commenting on MetroBiotech, MIB-626, NAD+ precursor therapy, kidney injury, or COVID-19 inflammation. The listed records are irrelevant name matches and unrelated media, so there is no public endorsement, mention, or contradiction here.
silent
No provided evidence shows Rajendra Apte discussing MetroBiotech, MIB-626, NAD+ precursor therapy, COVID-19 acute kidney injury, kidney inflammation, or the proposed NAD-restoration mechanism. The dossier places him in ophthalmology, ocular immunity, and macular degeneration, which is too far from this kidney-injury theory to count as a public mention.
Подтверждающие доказательства: The theory predicts paired biochemical and functional changes, which would give it explanatory force if observed.; The reasoning graph connects MetroBiotech's Friedreich's Ataxia and performance-oriented programs to tissue bioenergetic predictions.
Контрдоказательства: The listed publications are unrelated to MIB-626 or NAD+ bioenergetics, including trials on mirtazapine, vein location, and unrelated in silico phytochemistry.; No supplied evidence shows that MIB-626 improves cardiac bioenergetics, skeletal muscle bioenergetics, endurance, or muscle performance.; No supplied evidence separates NAD+ causality from alternative explanations.
Falsifiability8.0
This theory is easy to test and easy to wound. MIB-626 should raise NAD+ pathway metabolites, and treated participants should show measurable changes in cardiac bioenergetics, skeletal muscle bioenergetics, exercise metabolism, endurance, or muscle performance. A trial that raises NAD+ metabolites but shows no tissue-level bioenergetic or performance signal would directly damage the causal claim.
Подтверждающие доказательства: The theory makes concrete predictions about NAD+ pathway metabolites.; The theory names measurable tissue and functional endpoints: cardiac bioenergetics, skeletal muscle bioenergetics, exercise-related metabolism, endurance, and muscle performance.; The predictions can be tested against placebo or baseline values.
Контрдоказательства: The theory does not specify effect sizes, time windows, tissue assays, or minimum clinically meaningful changes.; Performance endpoints can be noisy unless trials control training status, disease severity, adherence, and motivation.
Дерево рассуждений
premise
MIB-626 is intended to raise NAD+ availability in treated participants.
medium confidence
premise
assumes
NAD+ — важный метаболический кофактор, участвующий в клеточном энергетическом обмене.
high confidence
assumption
requires
При Friedreich's Ataxia или в контекстах, где производительность является ограничивающим фактором, функция митохондрий нарушена или настолько ограничена, что доступность NAD+ может ограничивать биоэнергетику.
medium confidence
derivation
implies
Повышение доступности NAD+ должно улучшать энергетический метаболизм клеток, когда функция митохондрий нарушена или ограничивает его.
medium confidence
project_implication
implies
Программа MetroBiotech по Friedreich's Ataxia подразумевает, что MIB-626 может улучшить связанную с митохондриями биоэнергетику в поражённых тканях.
medium confidence
prediction
predicts
MIB-626-treated participants should show measurable changes in cardiac bioenergetics.
medium confidence
project_implication
implies
Ориентированная на повышение производительности программа MetroBiotech подразумевает, что MIB-626 может улучшать mitochondrial-linked bioenergetics в skeletal muscle или exercise-relevant tissues.
medium confidence
prediction
predicts
MIB-626-treated participants should show measurable changes in skeletal muscle bioenergetics.
medium confidence
prediction
predicts
MIB-626-treated participants should show measurable changes in exercise-related metabolism, endurance, or muscle performance.
medium confidence
prediction
predicts
У участников, получавших MIB-626, должно наблюдаться повышение уровня метаболитов пути NAD+.
Sinclair has publicly backed MetroBiotech's NAD booster thesis. In the 2017 video record, he says NAD+ has an important role in DNA repair and that NMN improved old mice's cells after treatment. In the MetroBiotech social post, he says the company is developing NAD boosters that mimic exercise and fasting responses and reports strong human-study results. That does not directly address Friedreich's Ataxia cardiac or skeletal muscle bioenergetics, but it is a clear public endorsement of the underlying claim that raising NAD+ can improve cellular function in disease.
The dossier includes no quotes from James Ellis and no company publications tied to him. The listed records appear to be unrelated uses of the same name, including Metro UK author pages, a food site biography, and a swimming video, none of which mention MetroBiotech, NAD+ therapy, Friedreich's Ataxia, or mitochondrial bioenergetics. On this evidence, he is publicly silent on the theory.
The provided evidence does not show Li-Huei Tsai publicly endorsing, mentioning, or contradicting MetroBiotech's NAD+ bioenergetics theory. The records are either about Andrew Huberman and NMN policy or a Boston Globe article on Alzheimer's memory research, and none supply a usable public statement from Tsai on this specific causal claim.
Lindsay Wu publicly discusses NMN as an NAD+ booster and says he and colleagues worked through MetroBiotech to develop it, which shows public alignment with NAD+ raising compounds. But the cited material does not directly endorse the narrower theory here: improved cardiac or skeletal muscle bioenergetics in Friedreich's Ataxia or another mitochondrial-linked disease, with measurable bioenergetic readouts.
Silent. The dossier includes no quotes from Nick Lane and no publications tied to MetroBiotech's Friedreich's Ataxia program or the claim that NAD+ precursor therapy improves cardiac or skeletal muscle bioenergetics. The listed records are irrelevant or ambiguous, including unrelated YouTube and library results, so they do not count as a public mention, endorsement, or contradiction of this theory.
silent
The provided public evidence places Rajendra Apte in ophthalmology, ocular immunity, macular degeneration, and an eye-disease startup. Nothing here shows him discussing MetroBiotech, NAD+ precursor therapy, or mitochondrial bioenergetics in Friedreich's Ataxia. On this record, he is publicly silent on the theory.
Подтверждающие доказательства: The theory would explain improved strength, endurance, exercise capacity, or training adaptation if those outcomes appeared after NAD+ precursor dosing.; The proposed mechanism has a plausible direction: better mitochondrial energy metabolism could contribute to performance changes.
Контрдоказательства: No included publication tests MIB-626 or another NAD+ precursor in a physical performance setting.; No included publication reports muscle NAD+ levels, mitochondrial function in muscle, VO2 max, endurance time, strength, or training adaptation.
Falsifiability8.0
This theory is testable. A randomized trial could dose MIB-626 or a related NAD+ precursor, alone or with high-intensity multidimensional training, and measure prespecified endpoints such as muscle strength, endurance, exercise capacity, and training adaptation. If those endpoints do not improve versus placebo under adequate dosing and adherence, the performance claim takes a direct hit.
Подтверждающие доказательства: The reasoning nodes make a concrete prediction: MIB-626 or related NAD+ precursor dosing should produce measurable improvements in physical performance endpoints.; The endpoint classes are named: muscle strength, endurance, exercise capacity, and adaptation to training.; The theory allows a specific design: standalone dosing or combination with structured high-intensity training.
Контрдоказательства: The theory text does not specify dose, duration, target population, minimum effect size, or which endpoint should move first.; Without a predefined threshold for success, small noisy changes could be overread.
Дерево рассуждений
premise
MetroBiotech's exercise and physical performance program implies that NAD+ precursor treatment is intended to improve muscle strength, endurance, or adaptation to training.
medium confidence
assumption
assumes
Дозирование предшественника NAD+ может повысить биологически значимую доступность NAD+ в скелетных мышцах или связанных с физической работоспособностью тканях.
medium confidence
premise
implies
Повышенная доступность NAD+ может поддерживать функцию митохондрий и клеточный энергетический обмен в мышцах.
medium confidence
derivation
implies
Если лечение предшественниками NAD+ улучшает функцию митохондрий и энергетический обмен, это может повысить физическую работоспособность мышц или адаптацию к тренировкам.
medium confidence
prediction
predicts
Дозирование MIB-626 или родственных предшественников NAD+ должно приводить к измеримым улучшениям показателей физической работоспособности.
medium confidence
prediction
predicts
Потенциальные конечные точки должны включать показатели мышечной силы, выносливости, переносимости физических нагрузок или адаптации к тренировкам.
medium confidence
assumption
assumes
Эффект дозирования предшественника NAD+ может быть обнаружен как при самостоятельном вмешательстве, так и в сочетании с высокоинтенсивной многокомпонентной физической тренировкой.
medium confidence
project_implication
requires
Соответствующая программа разработки должна проверять MIB-626 или родственные предшественники NAD+ по показателям физической работоспособности, включая комбинированные схемы со структурированными высокоинтенсивными тренировками.
medium confidence
observation
observed_in
Предоставленные подтверждающие публикации напрямую не оценивают предшественники NAD+, MIB-626, митохондриальную биологию мышц, выносливость при физических нагрузках, мышечную силу или адаптацию к тренировкам.
Sinclair publicly ties MetroBiotech's NAD boosters to exercise-like effects. In the Facebook post, he says the drugs are thought to mimic the benefits of exercise and fasting, and he links MIB-626 to ongoing human studies with strong results. The 2017 video record also connects NMN-based treatment to protection against muscle weakness in high-radiation settings. That is an endorsement of the core performance theory, even if he does not spell out a specific endurance endpoint.
No provided quote or publication shows James Ellis discussing MetroBiotech, NAD+ precursors, muscle performance, endurance, or exercise training. The records appear unrelated or identity-ambiguous, so there is no direct public endorsement, mention, or contradiction in this evidence set.
The evidence provided does not show Li-Huei Tsai publicly discussing MetroBiotech's theory that NAD+ precursor treatment could improve muscle performance or endurance. The records are either about Andrew Huberman and NMN policy, or a Boston Globe article about memory restoration work, which does not establish a public view from Tsai on exercise-performance effects.
The record ties Lindsay Wu to MetroBiotech and NAD+ raising compounds, and one linked publication is explicitly about improving physical performance with age. But the excerpts provided do not show Wu directly claiming that MIB-626 improves muscle strength, endurance, or training adaptation in humans. That is a public mention of the theme, not a clean, explicit endorsement of this specific theory.
The supplied evidence contains no usable public statement from Nick Lane about MetroBiotech, NAD+ precursor treatment, muscle performance, endurance, or exercise adaptation. The listed records appear unrelated, so there is no evidence here of endorsement, mention, or contradiction.
silent
Silent. The provided public evidence ties Rajendra Apte to ophthalmology, ocular immunity, macular degeneration, and Eyelten Therapeutics. It does not show him publicly discussing MetroBiotech, NAD+ precursor therapy, muscle performance, endurance, or exercise-related endpoints.
Подтверждающие доказательства: The theory connects one proposed mechanism, NAD+ restoration, to two expected outcomes: kidney function trajectory and inflammatory response.; The reasoning chain is internally coherent: MIB-626 to NAD+ availability, NAD+ availability to stress handling, stress handling to less renal injury progression.
Контрдоказательства: No supplied publication directly tests this mechanism or outcome pair.; Serum creatinine trajectories in COVID-19 acute kidney injury can change for many reasons unrelated to NAD+ restoration.; The evidence context provides no biomarker readout showing that inflammation changed because NAD+ biology changed.
Falsifiability8.0
This is the strongest Popperian feature. The theory makes trial-testable claims: MIB-626 should improve longitudinal serum creatinine trajectories and reduce inflammatory response versus placebo. Those claims can fail cleanly. If treated participants show no creatinine benefit, no inflammatory signal, or no evidence of NAD+ restoration in the relevant context, the theory takes a direct hit.
Подтверждающие доказательства: One prediction states that MIB-626 participants should show better longitudinal serum creatinine trajectories than placebo participants.; A second prediction states that MIB-626 participants should show reduced inflammatory response compared with placebo participants.; The proposed study population is specific: adults with COVID-19 and stage 1 acute kidney injury.
Контрдоказательства: The theory would be harder to falsify if the trial did not predefine the inflammatory markers, creatinine time window, or minimum clinically meaningful effect.; A null clinical result could still be blamed on dose, timing, or patient selection unless those conditions are locked before testing.
Дерево рассуждений
premise
MIB-626 предлагается в качестве вмешательства для взрослых с COVID-19 и острым повреждением почек 1-й стадии.
medium confidence
assumption
assumes
MIB-626 может восстановить или увеличить доступность NAD+ в соответствующем контексте почечного и воспалительного повреждения.
medium confidence
derivation
implies
Восстановление уровня NAD+ улучшает способность клеток справляться со стрессом при остром воспалительном повреждении и повреждении почек.
medium confidence
derivation
implies
Улучшенная способность клеток справляться со стрессом может замедлить прогрессирование повреждения почек при остром повреждении почек, связанном с COVID-19.
medium confidence
project_implication
implies
MIB-626 может предотвратить ухудшение функции почек у взрослых с COVID-19 и острым повреждением почек 1-й стадии.
medium confidence
prediction
predicts
У участников, получающих MIB-626, должны наблюдаться более благоприятные продольные траектории уровня креатинина в сыворотке, чем у участников, получающих плацебо.
high confidence
derivation
implies
Восстановление NAD+ во время острого воспалительного повреждения может ослабить воспалительный ответ.
medium confidence
project_implication
implies
MIB-626 может ослаблять воспалительный ответ у взрослых с COVID-19 и острым повреждением почек 1-й стадии.
medium confidence
prediction
predicts
У участников, получающих MIB-626, должна наблюдаться сниженная воспалительная реакция по сравнению с участниками, получающими плацебо.
high confidence
observation
observed_in
Предоставленные supporting publications напрямую не сообщают о данных, касающихся MIB-626, NAD+ restoration, COVID-19 acute kidney injury, serum creatinine trajectories или renal inflammatory outcomes.
Sinclair publicly talks about MetroBiotech, MIB-626, and NAD boosters, and he links NAD+ biology to cellular defense and DNA repair. The evidence here does not show him specifically endorsing the COVID-19 stage 1 acute kidney injury theory, its kidney-function endpoints, or its inflammatory-response claim. That is mention, not a direct public endorsement of this exact program theory.
The dossier contains no quote, publication, or company-related record tying this James Ellis to the theory about NAD+ restoration and acute kidney injury. The listed records are unrelated, including a swim video, Metro UK author pages, and a food site bio, so they do not count as a public mention, endorsement, or contradiction.
The provided evidence does not show Li-Huei Tsai discussing this kidney-injury theory, MIB-626, acute kidney injury, COVID-19 kidney outcomes, or NAD+ restoration in this context. The records are either unrelated to her or do not contain a statement from her on the theory, so public support, mention, or contradiction is not established here.
Lindsay Wu publicly discusses NAD+ boosting compounds and MetroBiotech in positive terms, including claims that NMN can improve DNA repair and that MetroBiotech is developing MIB-626 as an NAD booster. That is relevant to the broad NAD+ restoration idea. But none of the supplied records tie Wu directly to the specific claim that MIB-626 protects kidney function during COVID-19 acute kidney injury or reduces inflammatory worsening in that setting.
The evidence provided does not show Nick Lane discussing this theory, the COVID-19 acute kidney injury program, MIB-626, NAD+ restoration, or kidney injury. The records look unrelated or likely mismatched to a different Nick Lane, so there is no public endorsement, mention, or contradiction here.
silent
The provided evidence places Rajendra Apte in ophthalmology, ocular immunity, macular degeneration, and an ophthalmology startup. None of the quotes or publications tie him publicly to MetroBiotech, MIB-626, NAD+ restoration, acute kidney injury, or COVID-19 kidney protection. On this record, he stays silent on the theory.
Подтверждающие доказательства: The theory links oral dosing to measurable NAD+ and related metabolite increases.; It predicts pharmacodynamic evidence of NAD+ repletion in older adults after short-term treatment.; It extends beyond circulation by requiring muscle biopsy evidence.
Контрдоказательства: The supplied context does not include observed metabolite values, effect sizes, time courses, or biopsy results.; Blood, urine, and stool signals can fit alternative explanations that do not require tissue NAD+ repletion.; The unrelated publication list does not support this NAD+ precursor theory.
Falsifiability9.0
This theory is highly testable. It names the intervention, the compartments, the expected direction of change, and a target population. A controlled oral NMN or NAM study using labeled tracers, serial blood and urine sampling, stool metabolomics, and muscle biopsy could plainly refute the broad version if no NAD+ pathway enrichment appears, especially in muscle.
Подтверждающие доказательства: The predictions specify measurable increases in blood samples.; The predictions specify measurable increases in urine samples.; The predictions specify measurable increases in stool samples.; The predictions specify measurable increases in muscle biopsy samples.; The theory states that older adults should show pharmacodynamic evidence after short-term treatment.
Контрдоказательства: The theory does not specify dose, timing, minimum effect size, assay platform, or the exact metabolite panel.; Without predefined thresholds, weak or inconsistent changes could be interpreted too generously.
Дерево рассуждений
premise
Предшественники NAD+, принимаемые перорально, всасываются в организме человека.
medium confidence
derivation
implies
Поступившие предшественники NAD+ метаболизируются в NAD+ в организме человека.
medium confidence
derivation
implies
Метаболизм предшественников NAD+ происходит в мышцах и других тканях, а не только в кровообращении или экскреторных компартментах.
medium confidence
prediction
predicts
Меченый или немеченый NMN или NAM должен приводить к измеримому повышению уровня NAD+ и связанных с ним метаболитов в образцах биопсии мышечной ткани.
medium confidence
prediction
predicts
Прием NMN или NAM, маркированного или немаркированного, должен приводить к измеримому повышению уровня NAD+ и связанных с ним метаболитов в образцах крови.
medium confidence
assumption
assumes
Measured increases in NAD+ and related metabolites after NMN or NAM dosing are valid indicators of oral precursor absorption and metabolic flux into NAD+ pools.
medium confidence
prediction
predicts
Прием меченого или немеченого NMN или NAM должен приводить к измеримому повышению уровней NAD+ и родственных метаболитов в образцах мочи.
medium confidence
prediction
predicts
Прием NMN или NAM, независимо от наличия маркировки, должен приводить к измеримому повышению уровней NAD+ и связанных метаболитов в образцах кала.
medium confidence
prediction
predicts
Older adults should show pharmacodynamic evidence of NAD+ repletion after short-term NAD+ precursor treatment.
medium confidence
project_implication
requires
Testing this theory requires measuring NAD+ and related metabolites across blood, urine, stool, and muscle biopsy samples after oral NMN or NAM dosing, especially in older adults during short-term treatment.
Sinclair publicly backs the core claim that NAD+ precursors can raise NAD-related biology in vivo. In the 2017 video record, he discusses NMN as an NAD+ booster and says mouse treatment improved DNA-repair capacity, with human trials planned. In the later MetroBiotech post, he says the company is developing NAD boosters, that human studies of MIB-626 had been running for two years, and that the latest results were "amazing." That is stronger than a passing mention, even if the evidence here does not spell out the full tissue-level metabolomics theory in muscle biopsies.
No evidence here shows this James Ellis discussing oral NAD+ precursors, NMN, NAM, NAD+ repletion, or the company's theory. The records provided appear unrelated: a swim video, Metro UK author pages, and a food-site biography. On this dossier, he stays silent.
The dossier provides no quote, publication, or direct statement from Li-Huei Tsai about oral NMN, NAM, or NAD+ precursor uptake and tissue NAD+ repletion. The listed records are either unrelated to her or do not show her addressing this mechanism, so there is no public endorsement, mention, or contradiction here.
Lindsay Wu is publicly tied to NAD+ raising compounds and NMN through MetroBiotech, and one public record attributes to him the claim that "we believe we can with this molecule" in the context of NMN-based anti-aging therapy. That is a public mention of the broader NAD+ precursor idea, but the supplied evidence does not show him explicitly endorsing this narrower metabolic-flux claim about oral dosing, tissue NAD+ increases, or biopsy-based pharmacodynamics.
No relevant public statement appears in the provided evidence. The records are unrelated or likely refer to other people named Nick Lane, and none discuss oral NAD+ precursors, NAD+ repletion, NMN/NAM dosing, or this company theory.
silent
The provided evidence ties Rajendra Apte to ophthalmology, aging-related ocular immunity, macular degeneration, and Eyelten Therapeutics. It does not show any public statement from him on oral NAD+ precursors, NMN/NAM dosing, or NAD+ repletion in blood, muscle, or other tissues.
Подтверждающие доказательства: The theory gives a coherent causal chain: optimized NAD+ analog, NAD biology modulation, then possible disease-relevant effects.; The reasoning nodes identify the key hinge assumption: restoring NAD+ biology must causally influence the targeted pathology.
Контрдоказательства: No MIB-725 trial result is supplied.; No age-related disease, endpoint, or patient population is specified.; The evidence context does not show that NAD marker changes predict clinical benefit in the target disease.
Falsifiability7.0
This is testable. MIB-725 can fail on tolerability, fail to change NAD-related pharmacodynamic markers, or change markers without producing disease-relevant effects in later trials. The cleanest falsifier would be adequate human exposure with no target-tissue NAD modulation, because that would hit the program's core pharmacology rather than only its clinical translation.
Подтверждающие доказательства: The theory predicts tolerability in early human dosing.; The theory predicts modulation of NAD-related pharmacodynamic markers in treated humans.; The theory predicts disease-relevant biological effects in later trials if NAD+ restoration is causally linked to the targeted pathology.
Контрдоказательства: The disease context is broad, so a negative result in one indication may be reinterpreted as the wrong tissue, dose, marker, or population.; The marker criteria are not quantified, so the prediction needs predefined thresholds to be maximally falsifiable.
Дерево рассуждений
premise
Optimized proprietary NAD+ analog therapeutics may restore or sustain NAD+ biology more effectively than earlier NAD+ precursor approaches.
medium confidence
premise
assumes
NAD-linked biology is relevant to aging, metabolism, and age-related diseases.
medium confidence
assumption
requires
Восстановление биологии NAD+ может причинно влиять на биологические пути, участвующие в целевой возрастной патологии.
medium confidence
derivation
implies
Если MIB-725 успешно восстанавливает или модулирует биологию NAD+, он может оказывать терапевтическое действие при возрастных заболеваниях.
medium confidence
project_implication
implies
Программа MIB-725 компании MetroBiotech проверяет, могут ли аналоги NAD+ следующего поколения преобразовать биологию восстановления NAD+ в терапевтические средства для лечения возрастных заболеваний.
medium confidence
prediction
predicts
MIB-725 должен хорошо переноситься в ранних исследованиях дозирования у людей.
medium confidence
prediction
predicts
MIB-725 должен повышать или иным образом модулировать фармакодинамические маркеры, связанные с NAD, у людей, получавших лечение.
medium confidence
assumption
requires
Более новые проприетарные аналоги NAD+ способны обеспечить фармакологически значимое восстановление уровня NAD+ в соответствующих тканях человека.
medium confidence
prediction
predicts
Последующие испытания MIB-725 должны продемонстрировать биологические эффекты, связанные с заболеванием, если восстановление NAD+ причинно связано с целевой возрастной патологией.
medium confidence
assumption
requires
Фармакодинамические или биологические маркеры, релевантные заболеванию, в более поздних испытаниях являются валидными показателями пользы для целевого возрастного заболевания.
David Sinclair publicly promoted MetroBiotech's NAD booster program in social posts, describing the company as developing next-generation therapies for age-related disease, saying human-study results for MIB-626 were 'amazing,' and stating these advanced NAD boosters work better than existing ones in mice while discussing ongoing human trials.
The provided evidence contains no quotes or publications from James Ellis about MetroBiotech, NAD+ biology, MIB-725, or age-related disease. The listed records appear unrelated or are insufficient to attribute any view on the theory to this advisor.
The provided evidence does not show any public statement by Li-Huei Tsai about MetroBiotech's NAD+ analog theory. The NAD-related records only identify her as being on MetroBiotech's advisory board via a third-party podcast/article transcript, while the Boston Globe article quotes her on HDAC2 and Alzheimer's memory research, not NAD+ restoration or MIB-725.
Public records link Lindsay Wu to MetroBiotech and NAD+-raising compounds through equity/director disclosures and related aging-biology research, but the provided evidence does not show a direct public statement from him explicitly endorsing the specific theory behind MetroBiotech's next-generation NAD+ analog programs such as MIB-725.
No relevant public statement from Nick Lane about MetroBiotech's next-generation NAD+ analog theory appears in the provided evidence. The listed records are unrelated or ambiguous and do not discuss the theory.
silent
The provided evidence shows Rajendra Apte's academic and ophthalmology innovation roles and work on aging/AMD, but it does not include any public statement from him endorsing, mentioning, or contradicting MetroBiotech's NAD+ analog theory.
Explanatory power3.0
The theory explains what should happen after dosing, but it does not yet explain observed therapeutic outcomes because none are supplied. If NAD+ metabolites rise in blood, the precursor mechanism would explain that result better than lifestyle change or ordinary diet, assuming the trial controls those factors. It does not yet explain disease modification. The clinical bridge is still a hypothesis, and the provided publication set does not support it.
Подтверждающие доказательства: A pharmacologic precursor model has a cleaner causal path than indirect lifestyle explanations if dosing produces a timed rise in NAD+ metabolites.; The theory separates the near-term pharmacodynamic endpoint from later clinical outcome testing, which keeps the explanation from overclaiming.
Контрдоказательства: No supplied publication tests MIB-626, NAD+ elevation, or clinical outcomes tied to this program.; The publication examples shown concern unrelated topics, including mirtazapine for methamphetamine use disorder, tamarind extract, and pediatric vein localization.; Alternative explanations for any future clinical signal, including disease heterogeneity, placebo effects, and downstream pathway changes unrelated to NAD+ itself, are not addressed in the evidence context.
Falsifiability8.0
This is the strongest Popperian dimension. The theory makes a clear early test: dose MIB-626 and measure NAD+ plus related metabolites over days to weeks. It can fail plainly if levels do not rise, if exposure is too variable, or if safety signals block dosing. Later clinical claims are also testable, but the current theory has not specified disease, endpoint size, duration, or responder threshold, so the clinical falsification line is less sharp.
Подтверждающие доказательства: The theory predicts measurable increases in blood NAD+ and related metabolites within days to weeks.; The theory predicts that dosing can occur without unacceptable safety signals.; The evidence map states that clinical benefit claims depend first on pharmacodynamic elevation and tolerability.
Контрдоказательства: The clinical-outcome prediction is broad: age-related or mitochondrial-linked conditions could mean many diseases with different endpoints.; The prompt does not define the minimum NAD+ increase that would count as biologically meaningful.; Blood metabolite movement could be positive while the tissue-level mechanism still fails, which makes a partial result harder to interpret.
Дерево рассуждений
premise
Программа MIB-626 компании MetroBiotech утверждает, что запатентованный прекурсор NAD+ может фармакологически повышать доступность NAD+ у людей.
medium confidence
assumption
assumes
MIB-626 достаточно биодоступен у людей, чтобы после приема повысить системный уровень NAD+ или метаболитов, связанных с NAD+.
medium confidence
assumption
assumes
Повышения доступности субстрата-предшественника достаточно для восполнения пулов NAD+ в соответствующих тканях или компартментах человека.
medium confidence
derivation
implies
Если MIB-626 увеличивает доступность субстрата NAD+, тогда NAD-зависимые клеточные пути могут получать больше доступного NAD+ для своей активности.
medium confidence
derivation
implies
NAD-зависимые пути, на которые указывает теория, включают энергетический метаболизм, функцию митохондрий, регуляцию генов и реакцию на стресс.
medium confidence
prediction
predicts
Режим дозирования MIB-626 должен приводить к измеримому повышению уровня NAD+ в крови и родственных метаболитов в течение от нескольких дней до нескольких недель.
high confidence
project_implication
requires
The MIB-626 program depends first on demonstrating pharmacodynamic NAD+ elevation and tolerability before claiming clinical benefit.
high confidence
assumption
assumes
Blood NAD+ and related metabolites are acceptable measurable proxies for the intended pharmacologic increase in NAD+ availability.
medium confidence
prediction
predicts
Дозирование MIB-626 должно повышать доступность NAD+ без неприемлемых сигналов безопасности.
high confidence
prediction
predicts
If NAD+ elevation is achieved safely, later trials should be able to test whether NAD+ elevation translates into clinical outcomes in age-related or mitochondrial-linked conditions.
medium confidence
assumption
assumes
Elevating NAD+ in measurable compartments is plausibly connected to clinical benefit in age-related or mitochondrial-linked conditions.
David Sinclair publicly described MetroBiotech as developing 'NAD boosters,' said MIB-626 human-study results were 'amazing,' and stated these advanced NAD boosters work better than known alternatives. He also publicly promoted a clinical trial of MIB-626 as 'a form of NMN,' which supports the theory rather than contradicting it.
No provided quote, publication, or relevant record shows this James Ellis discussing MetroBiotech, MIB-626, NAD+ precursors, or the theory. The listed records appear unrelated or are likely about other people with the same name.
No attributable public quote, publication, or interview by Li-Huei Tsai was found that endorses, mentions, or contradicts MetroBiotech's claim that MIB-626 is an NAD+ precursor therapeutic. Publicly available company pages list her on MetroBiotech's scientific advisory board, but that is not a direct statement from her about the theory itself.
The provided public records tie Lindsay Wu to MetroBiotech and NAD+-raising compounds through equity, directorship, and related research, but they do not show him publicly stating that MIB-626 works as an NAD+ precursor therapeutic. The explicit MIB-626 endorsement in the evidence comes from David Sinclair, not Lindsay Wu.
No provided quote or company publication shows Nick Lane discussing MetroBiotech, MIB-626, NAD+ precursor therapeutics, or related claims. The listed records appear unrelated or are likely false matches, so there is no evidence here of endorsement, mention, or contradiction.
silent
The provided evidence describes Rajendra Apte's academic and ophthalmology work, aging-related research interests, and founder activity in macular degeneration, but it contains no public statement by Apte about MetroBiotech, MIB-626, NAD+ precursor therapeutics, or the underlying theory. The MetroBiotech records are not attributed to him.
